Health Care • Biotechnology: Pharmaceutical Preparations
$51.31 ▼ -0.14
(-0.27%)
MKT CAP: $958.5M • VOL: 174.4K
52W L $25 52W H $53
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$43
MEDIAN
$57
MEAN
$58
HIGH
$70
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE RIGL TAPE
RIGL // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $62.09 | $59.01 | 2025-02-14 | $46.69 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $64.65 | $60.55 | 2025-02-06 | $48.23 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $58.49 | $56.44 | 2025-01-29 | $49.26 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $52.34 | — | 2025-01-17 | $50.28 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $45.15 | $48.74 | 2025-01-09 | $45.67 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $61.06 | $53.36 | 2024-12-18 | $44.64 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $49.77 | $51.82 | 2024-12-04 | $47.72 | -4.3% | 48% | C |